Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

Key Takeaway: CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to presen
Price reaction · baseline $113.54 (2022-01-04 close) · hit after-hours · 1 other NTLA headline(s) in the window, move may be shared
day 0 close · peak
-9%
day 1
-7.9%
day 3
-8.2%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
9.6%
average across 8 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NTLA-2002
Phase 3 · Hereditary Angioedema

Full Press Release Details

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.
A live audio webcast of Intellia’s presentation can be accessed under the Events and Presentations page of the Investors & Media section on the company’s website at www.intelliatx.com. A replay of the audio webcast will be available on Intellia’s website for at least two weeks following the presentation.
About Intellia Therapeutics
Last updated: Jan 5, 2022